ALK lancerer ny vækststrategi og finansielle ambitioner for 2028
June 03, 2024 12:02 ET
|
ALK Abello
ALK (ALKB:DC / OMX: ALK B / AKBLF) har i dag meddelt, at bestyrelsen har vedtaget en ny selskabsstrategi (Allergy+) og finansielle ambitioner for 2028. Målet med Allergy+ er at udbygge ALK’s...
ALK launches new growth strategy and 2028 financial ambitions
June 03, 2024 12:02 ET
|
ALK Abello
ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that the Board of Directors has adopted a new corporate strategy (Allergy+) and 2028 financial ambitions. Allergy+ aims to further strengthen...
ALK presents positive phase 3 paediatric trial data offering new hope for children with respiratory allergies
June 03, 2024 01:00 ET
|
ALK Abello
At the Annual Congress of the European Academy of Allergy and Clinical Immunology (EAACI) which took part in Valencia in Spain from 31 May to 3 June 2024, the Danish pharmaceutical company ALK...
ALK’s European registration application for ITULAZAX® for paediatric indication accepted for review
May 30, 2024 07:44 ET
|
ALK Abello
ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that the European regulatory filing for ITULAZAX® (tree sublingual allergy immunotherapy (SLIT) tablet) in young children has been accepted for...
Listen in on ALK’s Capital Markets Day on 4 June 2024
May 29, 2024 04:56 ET
|
ALK Abello
ALK (ALKB:DC / OMX: ALK B / AKBLF) will host a Capital Markets Day on 4 June at 13.00-17.00. We cordially invite investors, analysts, and other interested stakeholders to listen in on our Capital...
Three-month interim report (Q1) 2024 (unaudited) - English version only
May 02, 2024 13:43 ET
|
ALK Abello
Bemærk venligst, at rapporten udelukkende forefindes på engelsk. Company release No. 11/2024 ALK delivers 10% organic revenue growth with operating profit up 41% in Q1 and upgrades outlookThe growth...
Three-month interim report (Q1) 2024 (unaudited)
May 02, 2024 13:43 ET
|
ALK Abello
Company release No. 11/2024 ALK delivers 10% organic revenue growth with operating profit up 41% in Q1 and upgrades outlookThe growth in ALK's overall sales was primarily driven by the European...
ALK opjusterer sine forventninger til salget for helåret
May 02, 2024 13:26 ET
|
ALK Abello
ALK opjusterer sine salgsforventninger for helåret ALK (ALKB:DC / OMX: ALK B / AKBLF) annoncerede i dag, at salgsforventningerne for helåret 2024 er blevet opjusteret. Omsætningen forventes nu at...
ALK upgrades its full-year revenue outlook
May 02, 2024 13:26 ET
|
ALK Abello
ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that the 2024 full-year financial outlook has been updated. Revenue is now expected to grow by 10-13% in local currencies (previously: 9-12%). The...
Invitation til præsentation af ALK’s regnskab for første kvartal fredag den 3. maj 2024
April 24, 2024 10:35 ET
|
ALK Abello
ALK (ALKB:DC / OMX: ALK B / AKBLF) offentliggør delårsrapport for de første tre måneder af 2024 (Q1) om morgenen fredag den 3. maj 2024. ALK afholder senere samme dag kl. 12.30 (CET) en...